Drug therapy in patients with chronic renal failure;Arzneimitteltherapie bei patienten mit chronischem nierenversagen

Deutsches Arzteblatt

Volumn 107, Issue 37, 2010, Pages 647-656

  Hartmann, Bertram ^a   Czock, David ^b   Keller, Frieder ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CARBAMAZEPINE; CEFEPIME; ENOXAPARIN; EPLERENONE; GABAPENTIN; GADOLINIUM; GLIBENCLAMIDE; GLIMEPIRIDE; GLIQUIDONE; LITHIUM; METFORMIN; METHOTREXATE; METOPROLOL; PETHIDINE; SPIRONOLACTONE;

CHRONIC KIDNEY FAILURE; COMORBIDITY; DRUG CONTRAINDICATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; REVIEW;

AGED; COMORBIDITY; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; METABOLIC CLEARANCE RATE; PRESCRIPTION DRUGS;

EID: 78649958350     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0647     Document Type: Review

References (48)

1. Corsonello A, Pedone C, Corica F, et al.: Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005; 165: 790-5.
2. Stevens LA, Nolin TD, Richardson MM, et al.: Chronic Kidney Disease Epidemiology Collaboration. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009; 54: 33-42.
3. Czock D, Bertsche T, Haefeli WE: Drug dose adjustments in patients with renal impairment. Am J Kidney Dis 2009; 54: 983-4.
4. Keller F: Nephrotoxische Störungen und nierenabhängige Arzneimittel. In: Risler T, Kühn K (eds.): Facharzt Nephrologie. München: Urban & Fischer 2008: 891-960.
5. Ludwig U, Riedel MK, Backes M, Imhof A, Muche R, Keller F: MESNA (Sodium 2-Mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity. Clin Nephrol 2010 (in press).
6. Kielstein JT, Schiffer M: Nephrogenic systemic fibrosis: a rare disease with grave consequences. Internist 2010; 51: 39-44.
7. Sonck J, Laureys G, Verbeelen D: The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 2008; 23: 966-70. (Pubitemid 351767571)
8. Karie S, Gandjbakhch F, Janus N, et al.: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology 2008; 47: 350-4.
9. Mahé I, Aghassarian M, Drouet L, et al.: Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97: 581-6. (Pubitemid 46592936)
10. Bendz H, Schön S, Attman PO, Aurell M: Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77: 219-24.
11. Almirall J, Bricullé M, Gonzalez-Clemente JM: Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice. Nephrol Dial Transplant 2008; 23: 2436-8. (Pubitemid 351957624)
12. Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A: The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54: 179-90.
13. Salem MM: Pathophysiology of hypertension in renal failure. Semin Nephrol. 2002; 22: 17-26.
14. Singh AK: Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010; 21: 2-6.
15. Cui Y, Wu Q, Zhou Y: Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int 2009; 76: 1137-41.
16. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-9.
17. De Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-84.
18. Aymanns C, Keller F, Maus S, Hartmann B, Czock D: Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010; 5: 314-327.
19. Onuigbo MA, Nye D, Iloanya PC: Drug-induced encephalopathy secondary to non renal dosing of common medications in two dialysis patients. Adv Perit Dial 2009; 25: 89-91.
20. Li YF, Fu S, Hu W et al.: Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007; 17: 739-63.
21. Boesler B, Czock D, Keller F et al.: Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 2005; 20: 1187-91. (Pubitemid 40862109)
22. Czock D, Keller F: Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 2007; 34: 727-51. (Pubitemid 350165274)
23. Czock D, Rasche FM: Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? Eur J Med Res 2005; 10: 145-8.
24. Hughes DW, Frei CR, Maxwell PR et al.: Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2014-9.
25. Czock D, Markert C, Hartman B, Keller F: Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol 2009; 5: 475-87.
26. e1. Levey AS, Stevens LA, Schmid CH, et al.: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
27. e2. Schou M, Kampf D: Lithium and the kidneys. In: Bauer M, Grof P, Mueller-Oerlinghausen B (eds.): Lithium in Neuropsychiatry. The comprehensive guide. London Infarma Healthcare 2006: 251-8
28. e3. Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 1984; 27: 351-7.
29. e4. Drüeke TB, Locatelli F, Clyne N, et al.: CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
30. e5. Singh AK, Szczech L, Tang KL, et al.: CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
31. e6. Pfeffer MA, Burdmann EA, Chen CY, et al.: TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-32.
32. e7. Tonelli M, Pannu N, Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312-24.
33. e8. Kunin CM, Rees SB, Merrill JP, Finland M: Persistence of antibiotics in blood of patients with acute renal failure. I. Tetracycline and chlortetracycline. J Clin Invest 1959; 38: 1487-97.
34. e9. Dost FH: Die Clearance. Klin Wochenschr 1949, 27: 257-64.
35. e10. Dettli L: Drug dosage in renal disease. Clin Pharmacokinet. 1976; 1: 126-34.
36. e11. Augsberger A: Quantitatives zur Therapie mit Herzglykosiden. II. Mitteilung. Kumulation und Abklingen der Wirkung. Klin Wochenschr 1954; 32: 945-51.
37. e12. Kunin CM: A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Ann Intern Med 1967; 67: 151-8.
38. e13. Gurwitz JH: Start low and go slow: dosing of antipsychotic medications in elderly patients with dementia. Arch Intern Med 1995; 155: 2017-8.
39. e14. Ehrlich P: Address in pathology on chemotherapeutics: Scientific principles, methods, and results. Lancet 1913; 4694: 445-51.
40. e15. Uhlig K, Macleod A, Craig J, et al.: Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058-65.
41. e16. Chennavasin P, Brater DC: Nomograms for drug use in renal disease. Clin Pharmacokinet. 1981; 6: 193-214.
42. e17. Segura J, Ruilope LM: Should diuretics always be included as initial antihypertensive management in early-stage CKD? Curr Opin Nephrol Hypertens 2009; 18: 392-6.
43. e18. Strippoli GF, Navaneethan SD, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006; 4: CD003967.
44. e19. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897-906.
45. e20. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF: Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009; 4: CD008175.
46. e21. Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC: Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2006; 4: CD006254.
47. e22. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007; 1: CD001890.
48. e23. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF: Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54: 619-37.